# A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

> **NCT04088409** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04088409
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-16
- **Primary completion:** 2023-07-17
- **Final completion:** 2028-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088409, "A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04088409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*